神经母细胞瘤
药理学
医学
业务
生物
遗传学
细胞培养
作者
Mineyoshi Aoyama,Kazuya Izumi,Hiromasa Aoki,Hiroki Kakita,Sho Takeshita,Hiroko Ueda,Yasumichi Inoue,Hidetoshi Hayashi,Yasumasa Yamada
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2023-12-01
卷期号:23 (11): 837-842
标识
DOI:10.2174/1568009623666230522113645
摘要
Background: Neuroblastoma is one of the most common childhood solid tumors. Because tumor suppressor genes are often hypermethylated in cancers, DNA methylation has emerged as a target for cancer therapeutics. Nanaomycin A, an inhibitor of DNA methyltransferase 3B, which mediates de novo DNA methylation, reportedly induces death in several types of human cancer cells. Objective: To study the antitumor activity of nanaomycin A against neuroblastoma cell lines and its mechanism. Methods: The anti-tumor effect of nanaomycin A on neuroblastoma cell lines was evaluated based on cell viability, DNA methylation levels, apoptosis-related protein expression, and neuronal-associated mRNA expression. Results: Nanaomycin A decreased genomic DNA methylation levels and induced apoptosis in human neuroblastoma cells. Nanaomycin A also upregulated the expression of mRNAs for several genes related to neuronal maturation. Conclusions: Nanaomycin A is an effective therapeutic candidate for treating neuroblastoma. Our findings also suggest that the inhibition of DNA methylation is a promising anti-tumor therapy strategy for neuroblastoma.
科研通智能强力驱动
Strongly Powered by AbleSci AI